Business Context and Reporting Period
MEDIROM Healthcare Technologies Inc., a Japan-based foreign private issuer, furnished this Form 6-K for December 2020, dated December 29, 2020. The filing reports the pricing and underwriting arrangements for the Company’s initial public offering.
Offering and Key Financial Terms
- The Company agreed to sell 800,000 American Depositary Shares (ADSs), with each ADS representing one common share.
- The offering price was $15.00 per ADS, before underwriting discounts and commissions.
- Gross proceeds implied by the base offering were approximately $12.0 million, before underwriting discounts, commissions, and offering expenses.
- The underwriter received a 45-day option to purchase up to an additional 120,000 ADSs at the offering price, representing potential additional gross proceeds of approximately $1.8 million.
- The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or balance-sheet metrics.
Material Changes Versus the Prior Comparable Period
The filing does not present comparative operating or financial results. The material event disclosed is the Company’s entry into the underwriting agreement and the planned initial public offering.
Guidance, Outlook, Risks, and Unusual Items
- The offering was expected to close on December 31, 2020, subject to customary closing conditions; the filing does not confirm subsequent completion.
- The offering was conducted under the Company’s effective Form F-1 registration statement and Form F-1MEF registration statement, both dated December 28, 2020.
- The Company cautioned that statements regarding the offering’s consummation and other future matters are forward-looking and subject to significant uncertainties and contingencies.
- Underwriting discounts, commissions, offering expenses, use of proceeds, dilution, and the final number of ADSs issued are not specified in the provided filing text.
Important Facts for Investors to Verify
- Whether the base offering and any underwriter overallotment option were completed, and the final ADS count issued.
- Net proceeds received after underwriting discounts, commissions, and offering expenses, and the Company’s stated use of proceeds.
- Any resulting changes in share capital, dilution, ownership, and outstanding ADSs.
- The Company’s subsequent financial condition, including cash, debt, liquidity, revenue, profitability, and cash flow.
- The full underwriting agreement and the related prospectus disclosures, including closing conditions and offering risks.